Pulmatrix Stock Price, News & Analysis (NASDAQ:PULM)

$1.48 0.01 (0.68 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$1.48
Today's Range$1.45 - $1.49
52-Week Range$0.88 - $6.98
Volume69,088 shs
Average Volume225,727 shs
Market Capitalization$30.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78

About Pulmatrix (NASDAQ:PULM)

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Debt-to-Equity RatioN/A
Current Ratio1.16%
Quick Ratio1.16%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$830,000.00
Price / Sales37.53
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book2.47

Profitability

Trailing EPSN/A
Net Income$-27,840,000.00
Net MarginsN/A
Return on Equity-175.74%
Return on Assets-113.66%

Miscellaneous

Employees24
Outstanding Shares21,050,000

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) released its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.08. The biotechnology company had revenue of $0.34 million for the quarter. View Pulmatrix's Earnings History.

When will Pulmatrix make its next earnings announcement?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Pulmatrix.

Who are some of Pulmatrix's key competitors?

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:

  • Mark T. Iwicki, Independent Chairman of the Board (Age 50)
  • Robert W. Clarke Ph.D., Chief Executive Officer, Director (Age 47)
  • William E. Duke Jr., Chief Financial Officer (Age 43)
  • David L. Hava Ph.D., Chief Scientific Officer (Age 41)
  • Jean Sung Ph.D., Vice President - Pharmaceutical Development
  • James M. Roach M.D., Chief Medical Officer
  • Amit D. Munshi, Director (Age 49)
  • Matthew L. Sherman M.D., Director (Age 61)
  • Steven H. Gillis Ph.D., Independent Director (Age 63)
  • Michael J. Higgins, Independent Director (Age 54)

How do I buy Pulmatrix stock?

Shares of Pulmatrix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of Pulmatrix stock can currently be purchased for approximately $1.48.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $30.94 million and generates $830,000.00 in revenue each year. Pulmatrix employs 24 workers across the globe.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (PULM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pulmatrix (NASDAQ:PULM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Pulmatrix (NASDAQ:PULM) Consensus Price Target History

Price Target History for Pulmatrix (NASDAQ:PULM)

Pulmatrix (NASDAQ:PULM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2017Dawson JamesReiterated RatingBuyMediumView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Pulmatrix (NASDAQ:PULM) Earnings History and Estimates Chart

Earnings by Quarter for Pulmatrix (NASDAQ:PULM)

Pulmatrix (NASDAQ PULM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018N/AView Earnings Details
11/9/2017Q3 2017($0.30)($0.22)$0.34 millionViewN/AView Earnings Details
8/4/2017Q2 2017($0.30)($0.29)ViewN/AView Earnings Details
5/5/2017Q1 2017($0.21)ViewN/AView Earnings Details
11/4/2016Q316($0.21)$0.06 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.62)ViewN/AView Earnings Details
5/5/2016Q1 2016($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.46)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.34)ViewN/AView Earnings Details
8/14/2015Q2 2015($2.08)ViewN/AView Earnings Details
2/12/2015Q4 2014($0.58)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.88)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.90)ViewN/AView Earnings Details
6/30/2014Q414($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pulmatrix (NASDAQ:PULM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.95 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS

Dividends

Dividend History for Pulmatrix (NASDAQ:PULM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pulmatrix (NASDAQ PULM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.11%
Institutional Ownership Percentage: 19.96%
Insider Trades by Quarter for Pulmatrix (NASDAQ:PULM)

Pulmatrix (NASDAQ PULM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2015David MakiDirectorBuy72,750$6.88$500,520.00View SEC Filing  
6/16/2015Steven GillisDirectorBuy72,750$6.88$500,520.00View SEC Filing  
6/15/2015Terrance McguireDirectorBuy106,693$6.88$734,047.84View SEC Filing  
6/15/2015Terrance McguireDirectorBuy106,693$6.88$734,047.84View SEC Filing  
3/23/2015Innovative Sciences In OculusMajor ShareholderSell350,000$2.75$962,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pulmatrix (NASDAQ PULM) News Headlines

Source:
DateHeadline
How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
finance.yahoo.com - December 19 at 4:32 PM
Pulmatrix Inc (PULM): Time For A Financial Health CheckPulmatrix Inc (PULM): Time For A Financial Health Check
finance.yahoo.com - December 5 at 12:03 PM
Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:26 AM
FY2017 Earnings Estimate for Pulmatrix, Inc. (PULM) Issued By Zacks Investment ResearchFY2017 Earnings Estimate for Pulmatrix, Inc. (PULM) Issued By Zacks Investment Research
www.americanbankingnews.com - November 17 at 8:08 PM
PULM: Business And Financial Update For Third Quarter 2017PULM: Business And Financial Update For Third Quarter 2017
finance.yahoo.com - November 15 at 7:45 AM
Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated FinancialsPulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials
finance.yahoo.com - November 12 at 11:57 AM
Pulmatrix, Inc. (PULM) Releases Quarterly  Earnings Results, Beats Expectations By $0.08 EPSPulmatrix, Inc. (PULM) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - November 10 at 7:54 PM
Pulmatrix (PULM) to Present at North American Cystic Fibrosis Conference - StreetInsider.comPulmatrix (PULM) to Present at North American Cystic Fibrosis Conference - StreetInsider.com
www.streetinsider.com - November 2 at 8:01 AM
Pulmatrix Presents at the North American Cystic Fibrosis ConferencePulmatrix Presents at the North American Cystic Fibrosis Conference
finance.yahoo.com - November 1 at 7:47 AM
Pulmatrix (PULM) Appoints Dr. James Roach as CMOPulmatrix (PULM) Appoints Dr. James Roach as CMO
www.streetinsider.com - October 31 at 8:20 AM
Pulmatrix Appoints Dr. James Roach as Chief Medical OfficerPulmatrix Appoints Dr. James Roach as Chief Medical Officer
finance.yahoo.com - October 31 at 8:20 AM
Pulmatrix, Inc. (PULM) Scheduled to Post Quarterly Earnings on ThursdayPulmatrix, Inc. (PULM) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - October 26 at 3:46 AM
Pulmatrix: Company to Watch in Lung Disease MarketPulmatrix: Company to Watch in Lung Disease Market
finance.yahoo.com - October 25 at 9:28 AM
Is It Time To Buy Pulmatrix Inc (PULM)?Is It Time To Buy Pulmatrix Inc (PULM)?
finance.yahoo.com - October 12 at 8:36 AM
Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1%Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1%
seekingalpha.com - October 5 at 5:53 PM
Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDAPulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
finance.yahoo.com - October 3 at 11:14 AM
Pulmatrix, Inc. (PULM) to Post FY2017 Earnings of ($0.90) Per Share, Dawson James ForecastsPulmatrix, Inc. (PULM) to Post FY2017 Earnings of ($0.90) Per Share, Dawson James Forecasts
www.americanbankingnews.com - October 2 at 3:44 AM
Pulmatrix, Inc. (PULM) Rating Reiterated by Dawson JamesPulmatrix, Inc. (PULM) Rating Reiterated by Dawson James
www.americanbankingnews.com - September 30 at 7:34 AM
Todays Research Reports on Trending Tickers: Opko Health and PulmatrixToday's Research Reports on Trending Tickers: Opko Health and Pulmatrix
finance.yahoo.com - September 27 at 8:23 AM
Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017
finance.yahoo.com - September 22 at 2:52 PM
PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In PulmatrixPULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix
finance.yahoo.com - September 20 at 8:01 AM
CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few MonthsCEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months
finance.yahoo.com - September 20 at 8:01 AM
Is It The Right Time To Buy Pulmatrix Inc (PULM)?Is It The Right Time To Buy Pulmatrix Inc (PULM)?
finance.yahoo.com - September 20 at 8:01 AM
Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017
finance.yahoo.com - September 9 at 7:38 AM
Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal InfectionsPulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections
finance.yahoo.com - September 5 at 3:53 PM
Daily Technical Summary Reports on Biotech Stocks -- Paratek Pharma, Pulmatrix, Verastem, and BiostageDaily Technical Summary Reports on Biotech Stocks -- Paratek Pharma, Pulmatrix, Verastem, and Biostage
www.prnewswire.com - August 24 at 11:30 AM
Pulmatrix, Inc. (PULM) Issues Quarterly  Earnings Results, Beats Estimates By $0.01 EPSPulmatrix, Inc. (PULM) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 5 at 12:10 PM
Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated FinancialsPulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials
finance.yahoo.com - August 5 at 6:25 AM
PULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPDPULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPD
finance.yahoo.com - August 4 at 7:19 AM
Pulmatrix Strengthens Its Financials and Improves OutlookPulmatrix Strengthens Its Financials and Improves Outlook
finance.yahoo.com - August 1 at 4:10 AM
Cystic Fibrosis Therapeutics Pipeline H1 2017 Research Report Available at RnR Market ResearchCystic Fibrosis Therapeutics Pipeline H1 2017 Research Report Available at RnR Market Research
www.bizjournals.com - July 1 at 6:46 AM
Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN...Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN...
www.finanznachrichten.de - May 19 at 12:12 PM
Pulmatrix Receives Key US Patent for its Inhaled Drug for COPDPulmatrix Receives Key US Patent for its Inhaled Drug for COPD
www.nasdaq.com - May 9 at 10:58 AM
Pulmatrix (PULM) Appoints Ted Raad as CBOPulmatrix (PULM) Appoints Ted Raad as CBO
www.streetinsider.com - May 5 at 7:39 PM
BRIEF-Pulmatrix reports qtrly loss per share $0.21BRIEF-Pulmatrix reports qtrly loss per share $0.21
www.reuters.com - May 5 at 7:39 PM
Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board - PR Newswire (press release)Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board - PR Newswire (press release)
www.prnewswire.com - March 29 at 12:12 AM
Form 4 Pulmatrix, Inc. For: Mar 20 Filed by: Sherman Matthew L - StreetInsider.comForm 4 Pulmatrix, Inc. For: Mar 20 Filed by: Sherman Matthew L - StreetInsider.com
www.streetinsider.com - March 23 at 12:22 AM
Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent (PULM)Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent (PULM)
www.investopedia.com - March 22 at 7:21 PM
Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient CareBiotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
www.prnewswire.com - March 22 at 8:49 AM
Why Pulmatrix Investors Are Breathing a Sigh of ReliefWhy Pulmatrix Investors Are Breathing a Sigh of Relief
us.rd.yahoo.com - March 21 at 7:10 PM
Pulmatrix (PULM) Shows Strength on Market Open After Announcing PatentPulmatrix (PULM) Shows Strength on Market Open After Announcing Patent
www.streetinsider.com - March 21 at 10:45 AM
PULMATRIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsPULMATRIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 17 at 7:30 PM
Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma - PR Newswire (press release)Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma - PR Newswire (press release)
www.prnewswire.com - March 11 at 7:12 PM
BRIEF-Pulmatrix reports 2016 financial results providesBRIEF-Pulmatrix reports 2016 financial results provides
www.reuters.com - March 10 at 9:13 PM
Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease PipelinePulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline
us.rd.yahoo.com - March 10 at 9:13 PM
PULMATRIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsPULMATRIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 9:13 PM
PULMATRIX, INC. Files SEC form 8-K, Change in Directors or Principal OfficersPULMATRIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 3 at 7:27 PM
PULMATRIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other EventPULMATRIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Event
us.rd.yahoo.com - February 8 at 9:38 PM
Pulmatrix Announces $3.33M Registered Direct Issue (PULM)Pulmatrix Announces $3.33M Registered Direct Issue (PULM)
www.investopedia.com - February 7 at 10:07 PM
Pulmatrix Announces $3.33M Registered Direct IssuePulmatrix Announces $3.33M Registered Direct Issue
www.investopedia.com - February 7 at 10:07 PM

SEC Filings

Pulmatrix (NASDAQ:PULM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pulmatrix (NASDAQ:PULM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pulmatrix (NASDAQ PULM) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.